World’s First Long-Acting Anti-RSV Monoclonal Antibody Xinduotuo Wins NMPA Approval — Medicilon Empower Trinomab’s Source Innovation

September 3, 2026 — The world’s first fully human long-acting anti-RSV monoclonal antibody, Xinduotuo (generic name: retavibart injection; development code: TNM001), independently developed by Zhuhai Trinomab Pharmaceutical Co., Ltd. (STAR Market: 688806, “Trinomab”), has received marketing approval from China’s National Medical Products Administration (NMPA). It is indicated for the prevention of RSV-associated lower respiratory tract […]